Prosecution Insights
Last updated: September 26, 2026
Application No. 17/906,962

ANTI-INFLAMMATORY IMMUNOENHANCER

Non-Final OA §103§112§DP
Filed
Sep 21, 2022
Priority
Mar 25, 2020 — JP 2020-054032 +1 more
Examiner
WELLS, LAUREN QUINLAN
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Scent Science International Inc.
OA Round
3 (Non-Final)
48%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allowance Rate
119 granted / 247 resolved
-11.8% vs TC avg
Strong +60% interview lift
Without
With
+59.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
79 currently pending
Career history
312
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
36.5%
-3.5% vs TC avg
§102
14.5%
-25.5% vs TC avg
§112
26.8%
-13.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 247 resolved cases

Office Action

§103 §112 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 06/23/2026 has been entered. The amendment filed 05/20/2026, cancelled claims 9, 12-18 and 17, and amended claim 10. Claims 10, 15-16 and 18 are pending. Priority This application claims the following priority: PNG media_image1.png 98 668 media_image1.png Greyscale Election/Restrictions Applicant elected PNG media_image2.png 101 116 media_image2.png Greyscale , 2-methyl-2-thiazoline, as the species of the compound, in the reply filed on 06/24/2025. The elected species is free of the prior art. The examination of the Markush claim has been extended. If a Markush grouping as set forth in a claim is proper and election of species has been required, the examiner must continue to search the species of the claim unless the claim has been found to be unpatentable over prior art. MPEP 803.02. The search has been extended to PNG media_image3.png 113 118 media_image3.png Greyscale . Claim 16 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected subject matter, there being no allowable generic or linking claim. Claims 10, 15, and 18 are examined on the merits herein. REJECTIONS WITHDRAWN The status for each rejection and/or objection in the previous Office Action is set out below. Claim Objections Applicant’s deletion of claim 9 and amendment to claim 10 is sufficient to overcome this objection. 35 U.S.C. § 102 and 103 over Wagle Regarding the 102 rejection, Wagle does not explicitly teach a method of administering 2-methyl-2-thiazole to a patient in need of suppressed inflammation. Moreover, while [0003] of Wagle teaches advanced glycosylation end products as inflammatory mediators, it does not specifically teach 2-methyl-2-thiazole as having this property. And while Wagle teaches its compounds for the treatment of intraocular pressure, it does not exemplify or explicitly teach a method of treating intraocular pressure by administering 2-methyl-thiazole, or teach intraocular pressure as causing inflammation. Regarding the 103 rejection, while Wagle teaches its compounds, generically, as treating “Certain Fibrotic Diseases” ([0037]), it additionally teaches its compounds as treating Arteriosclerosis, Atherosclerosis, Stiff Vessel Disease, Peripheral Vascular Disease, Coronary Heart Disease, Stroke, Myocardial Infarct, Cardiomyopathies, Restenosis, Bladder Elasticity, Macular Degeneration, ALS, Rheumatoid Arthritis, Osteoarthritis, Bone Resorption, Dialysis, Asthma, Carpal Tunnel Syndrome, and more disparate diseases, in a laundry list of diseases. As such, there is no motivation to specifically select 2-methyl-2-thiazoline or 2,4,5-trimethylthiazole to treat fibrotic disease, or any of the other generally taught diseases of Wagle. Moreover, on pg. 9, Remarks, Applicant persuasively argues that “In other words, Meneghin et al. teaches that an anti-inflammatory immune skewing does not necessarily mean an enhancement of host defense,” in reference to fibrotic disease. For these reasons, the prior art rejections over Wagle are withdrawn. Double Patenting In view of the 04/01/2026 claim amendments to Application No. 18/040,569, the Double Patenting rejection is withdrawn. The patient population of the instant claims and that of ‘569 are distinct. NEW REJECTIONS The rejections are new. Improper Markush Grouping Claims 10 and 15 are rejected on the basis that it contains an improper Markush grouping of alternatives. See In re Harnisch, 631 F.2d 716, 721-22 (CCPA 1980) and Ex parte Hozumi, 3 USPQ2d 1059, 1060 (Bd. Pat. App. & Int. 1984). A Markush grouping is proper if the alternatives defined by the Markush group (i.e., alternatives from which a selection is to be made in the context of a combination or process, or alternative chemical compounds as a whole) share a “single structural similarity” and a common use. A Markush grouping meets these requirements in two situations. First, a Markush grouping is proper if the alternatives are all members of the same recognized physical or chemical class or the same art-recognized class, and are disclosed in the specification or known in the art to be functionally equivalent and have a common use. Second, where a Markush grouping describes alternative chemical compounds, whether by words or chemical formulas, and the alternatives do not belong to a recognized class as set forth above, the members of the Markush grouping may be considered to share a “single structural similarity” and common use where the alternatives share both a substantial structural feature and a common use that flows from the substantial structural feature. See MPEP § 2117. The Markush grouping of formula (I), PNG media_image4.png 140 170 media_image4.png Greyscale PNG media_image5.png 308 624 media_image5.png Greyscale , is improper because the alternatives defined by the Markush grouping do not share both a single structural similarity. Formula (I) contains no singular structural similarity aside from being rings with heteroatoms. Ring A comprises: -5 membered rings, 6 membered rings, bicyclic rings, and tricyclic rings; -aromatic rings, aliphatic rings, and rings with a single double bond; and -one or two heteroatoms of different combinations of O, S, N, and N-N. Thus, formula (I) encompasses a wide variety of chemical species classified in distinct physical classes, wherein these chemical species do not share any single structural similarity. While the compounds are claimed to have the same use, i.e., enhancing immunity and suppressing inflammation, there is no significant structural feature or core from which the utility flows. To overcome this rejection, Applicant may set forth each alternative (or grouping of patentably indistinct alternatives) within the improper Markush grouping in a series of independent or dependent claims and/or present convincing arguments that the group members recited in the alternative within a single claim in fact share a single structural similarity as well as a common use. To overcome this rejection, Applicant can amend the claims to the following structure: PNG media_image6.png 105 133 media_image6.png Greyscale . Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 10, 15, and 18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In the claim 10, the phrase “enhancing immunity” renders the claim indefinite. The term “enhancing” in reference to immunity, is a relative term that is neither defined by the specification nor the prior art. It is not clear what baseline is being referenced to determine “enhancing.” Specifically, it is not clear if “enhancing” is the elevation of a certain biomarker in vivo, or the amelioration of a specific outward symptom, or something else entirely. And it is not clear if the baseline for “enhancing immunity” is being determined by a specific immunity baseline known in the art, or is being determined by a specific measure of a biomarker/symptom of the individual mammal prior to administration of instant formula (I). All other claims not specifically recited are rejected for depending from an indefinite claim and failing to cure the deficiency. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 10 and 15 are rejected under 35 U.S.C. 103 as being unpatentable over US 2014/0018400 to Schmidt (published 2014, PTO-892) as evidenced by Viswanath (Understanding Autoimmune Diseases-A Review, published 2013, PTO-892). Schmidt teaches a method of treating autoimmune disorders by administering compounds of formula, PNG media_image7.png 126 148 media_image7.png Greyscale (pg. 43, claims 1, 8), such as PNG media_image8.png 113 118 media_image8.png Greyscale (pg. 44, claim 47; [0340], [0351]). PNG media_image8.png 113 118 media_image8.png Greyscale meets the limitations of instant formula (I) when A is a thiazole, R1 is H, R2 is a C1alkyl, R3 is an oxo group, and R4 is a C6-aryl group. While Schmidt teaches a method of treating autoimmune disorders and teaches PNG media_image8.png 113 118 media_image8.png Greyscale , as a preferred compound, it differs from that of instant claim 10 in that it does not explicitly teach a method of treating autoimmune disorders by administering PNG media_image8.png 113 118 media_image8.png Greyscale . It would have been prima facie obvious to one of ordinary skill in the art, prior to the effective filing date of the instantly claimed invention, to select PNG media_image8.png 113 118 media_image8.png Greyscale as the compound administered in the methods of treating an autoimmune disease of Schmidt, to arrive at instant claim 10. One of ordinary skill in the art would have been motivated to make such a selection, with a reasonable expectation of success, because: -Schmidt teaches autoimmune diseases as a disease preferably treated by its methods, and -Schmidt teaches PNG media_image8.png 113 118 media_image8.png Greyscale , as one of six preferred compounds with excellent activity for use in its treatment methods (see Compound 5, [0365]-[0367]). As such, an ordinary skilled artisan would have been motivated to make such a selection to predictably arrive at an effective method of treating autoimmune diseases. Regarding claim 10, while Schmidt does not explicitly teach “ “enhancing immunity and suppressing inflammation in an animal in need thereof,” it teaches the same step of administering an effective amount of a compound of formula (I), i.e., PNG media_image8.png 113 118 media_image8.png Greyscale , to a mammal; the instant specification teaches an effective amount as 1pg/kg to 5,000mg/kg ([0058]), and Schmidt teaches an effective amount as 0.01-500mg/kg/day ([0212]). The instant specification does not define a mammal in need of enhanced immunity. Since all mammals benefit from enhanced immunity, i.e., protection from viruses, protection from bacteria, and protection from the growth of cancerous cells, for example, the patient population of Schmidt meets the limitation of “a patient in need of enhanced immunity.” Regarding “suppressing inflammation,” as evidenced by Viswanath, autoimmune disorders cause chronic inflammation, causing pain and permanent changes or damages to the involved tissue. Thus, a mammal with an autoimmune disorder is a mammal in need of suppressed inflammation and enhanced immunity. Regarding claim 15, PNG media_image8.png 113 118 media_image8.png Greyscale meets the limitations of instant formula (I) when A is a thiazole, R1 is H, R2 is a C1alkyl, R3 is an oxo group, and R4 is a C6-aryl group. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 10, 15 and 18 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 11,590,141 (PTO-892 of 08/27/2025), as evidenced by Bartels (Hypoxia and inflammation are two sides of the same coin, published 2013, PTO-892). Claims 10, 15 and 18 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-8 of U.S. Patent No. 12,076,325 (PTO-892 of 08/27/2025), as evidenced by Francisco (Inflammation in Myocardial Ischemia/Reperfusion Injury: Underlying Mechanisms and Therapeutic Potential, published 2023, PTO-892). Although the claims at issue in each of the patents are not identical, they are not patentably distinct from each other. ‘141 claims a method for treating hypoxic injury in a mammal comprising administering a compound of PNG media_image9.png 105 133 media_image9.png Greyscale (claim 1). ‘141 claims 2-methyl-2-thiazoline and additional species (claims 2, 4-8). ‘325 claims a method for treating ischemia-reperfusion in a mammal comprising administering a compound of PNG media_image9.png 105 133 media_image9.png Greyscale (claim 1). ‘325 claims 2-methyl-2-thiazoline and additional species (claims 2, 4-8). Regarding claim 10, while ‘141 and ‘325 do not explicitly teach “ “enhancing immunity and suppressing inflammation in an animal in need thereof,” they teach the same step of administering an effective amount of a compound of formula (I), i.e., PNG media_image9.png 105 133 media_image9.png Greyscale , to a mammal; the instant specification teaches an effective amount as 1pg/kg to 5,000mg/kg ([0058]), and ‘325 and ‘141 teach an effective amount as 0.1ug-5000mg/kg/day (Col. 13, lines 60-67 and Col. 14, lines 7-32, respectively). The instant specification does not define a mammal in need of enhanced immunity. Since all mammals benefit from enhanced immunity, i.e., protection from viruses, protection from bacteria, and protection from the growth of cancerous cells, for example, the patient population of ‘141 and ‘325 meet the limitation of “a patient in need of enhanced immunity,” as instantly claimed. Regarding “suppressing inflammation,” as evidenced by Bartels, hypoxia causes inflammation, and as evidenced by Francisco ischemia-reperfusion injury causes inflammation Thus, a mammal with hypoxia is a mammal in need of suppressed inflammation and enhanced immunity. Claims 10 and 15 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3, 15-16 of copending Application No. 18/785,986 (claim set of 07/26/2024). This is a provisional nonstatutory double patenting rejection. ‘986 claims a method for preventing or treating hypoxic injury, ischemia-reperfusion injury or inflammation in a mammal comprising administering a compound of instant formula (I) (claims 1, 15, 16). Regarding claim 10, while ‘’986 does not explicitly teach “ “enhancing immunity and suppressing inflammation in an animal in need thereof,” it teaches the same step of administering an effective amount of a compound of formula (I) to a mammal; the instant specification teaches an effective amount as 1pg/kg to 5,000mg/kg ([0058]), and ‘986 teaches an effective amount as 0.1ug-5000mg/kg/day ([0052]). The instant specification does not define a mammal in need of enhanced immunity. Since all mammals benefit from enhanced immunity, i.e., protection from viruses, protection from bacteria, and protection from the growth of cancerous cells, for example, the patient population of ‘986 meets the limitation of “a patient in need of enhanced immunity,” as instantly claimed. Regarding “suppressing inflammation,” ‘986 claims its methods for treating inflammation. Free of the Prior Art Claim 18 is free of the prior art. The closest prior art is US 2002/0183317 to Wagle (published 2002, PTO-892 of 08/27/2025), which teaches 2-methyl-2-thiazoline or 2,4,5-trimethylthiazole and teaches methods of treating fibrotic disease. However, Wagle does not explicitly teach a method of administering 2-methyl-2-thiazoline or 2-methyl-2-thiazole to a patient in need of suppressed inflammation. While Wagle teaches its compounds, generically, as treating “Certain Fibrotic Diseases” ([0037]), it additionally teaches its compounds as treating Arteriosclerosis, Atherosclerosis, Stiff Vessel Disease, Peripheral Vascular Disease, Coronary Heart Disease, Stroke, Myocardial Infarct, Cardiomyopathies, Restenosis, Bladder Elasticity, Macular Degeneration, ALS, Rheumatoid Arthritis, Osteoarthritis, Bone Resorption, Dialysis, Asthma, Carpal Tunnel Syndrome, and more disparate diseases, and teaches a plethora of species of its generic compound. As such, there is no motivation to specifically select 2-methyl-2-thiazoline or 2,4,5-trimethylthiazole to treat fibrotic disease, or any of the other diseases taught by Wagle. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAUREN WELLS whose telephone number is (571)272-7316. The examiner can normally be reached M-F 7:00-4:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James (Jim) Alstrum-Acevedo can be reached on 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAUREN WELLS/Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Show 2 earlier events
Nov 25, 2025
Response Filed
Feb 23, 2026
Final Rejection mailed — §103, §112, §DP
May 20, 2026
Response after Non-Final Action
Jun 23, 2026
Request for Continued Examination
Jun 24, 2026
Response after Non-Final Action
Sep 10, 2026
Response after Non-Final Action
Sep 11, 2026
Non-Final Rejection mailed — §103, §112, §DP
Sep 24, 2026
Examiner Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12740980
Methods of Treating Ischemic Disease by Administering an ATR Kinase Inhibitor
3y 0m to grant Granted Sep 22, 2026
Patent 12740968
METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO HYDROGEN SULFIDE
2y 7m to grant Granted Sep 22, 2026
Patent 12728117
MrgprX2 Antagonists for the Treatment of Inflammatory Disorders
11m to grant Granted Sep 08, 2026
Patent 12721854
INACTIVATION OF PATHOGENS USING METAL-BASED COORDINATION COMPLEXES, AND METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING MICROBIAL AND/OR VIRAL INFECTIONS
5y 6m to grant Granted Sep 01, 2026
Patent 12714708
COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING HER2 EXON 19 MUTATIONS
5y 11m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
48%
Grant Probability
99%
With Interview (+59.8%)
3y 0m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 247 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month